The study of immune checkpoint inhibitors in chronic hepatitis B virus infection

Siyu Li; Na Li; Shanru Yang; Haiyan Deng; Yanguo Li; Yixuan Wang; Jiaqiang Yang; Jiaxin Lv; Lan Dong; Guansen Yu; Xin Hou; Geng Wang

doi:10.1016/j.intimp.2022.108842

The study of immune checkpoint inhibitors in chronic hepatitis B virus infection

Int Immunopharmacol. 2022 Aug:109:108842. doi: 10.1016/j.intimp.2022.108842. Epub 2022 May 12.

Authors

Siyu Li¹, Na Li¹, Shanru Yang², Haiyan Deng¹, Yanguo Li³, Yixuan Wang¹, Jiaqiang Yang¹, Jiaxin Lv¹, Lan Dong¹, Guansen Yu¹, Xin Hou¹, Geng Wang⁴

Affiliations

¹ School of Medicine, Ningbo University, Ningbo 315211, China.
² School of Medicine, Ningbo University, Ningbo 315211, China; Department of Histology and Embryology, Harbin Medical University, Harbin 150081, China.
³ Institute of Drug Discovery Technology, Ningbo University, Ningbo, China.
⁴ School of Medicine, Ningbo University, Ningbo 315211, China. Electronic address: wanggeng@nbu.edu.cn.

PMID: 35569306
DOI: 10.1016/j.intimp.2022.108842

Abstract

Chronic hepatitis B (CHB) is a contagious disease caused by the hepatitis B virus, which can damage the liver via cirrhosis or cancer. Existing CHB treatments are not completely effective; immune checkpoint inhibitors show potential hope for treating CHB, but their safety and efficacy need to be further validated. In this review, we introduce the mechanisms of CHB virus infection, the expression of immune checkpoints during CHB, and the treatments that are currently available. Finally, we discuss the possibilities for using immune checkpoint inhibitors to treat CHB.

Keywords: Chronic hepatitis B; Hepatitis B virus; Immune checkpoint inhibitors.

Publication types

Review

MeSH terms

Hepatitis B virus
Hepatitis B, Chronic*
Humans
Immune Checkpoint Inhibitors / therapeutic use
Liver Cirrhosis
Liver Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors